Breaking News Instant updates and real-time market news.

CHRS

Coherus Biosciences

$20.65

-2.05 (-9.03%)

06:46
06/12/17
06/12
06:46
06/12/17
06:46

Coherus Biosciences down about 9% after receiving CRL for CHS-1701

In pre-market trading, shares are down 8.72% to $18.85.

CHRS Coherus Biosciences
$20.65

-2.05 (-9.03%)

05/17/17
MAXM
05/17/17
NO CHANGE
Target $44
MAXM
Buy
Coherus could beat Humira competitors to market by 4 years, says Maxim
Maxim analyst Jason McCarthy said the invalidation of AbbVie's (ABBV) dosing patent for Humira is a "major victory" for Coherus Biosciences (CHRS) that has reduced its risk profile. The last IP hurdle to launching a Humira biosimilar is formulation, where Coherus has the advantage, said McCarthy, who believes the company could be first to market with a biosimilar by late 2018, which would be four years or more ahead of its competition. He raised his price target on Coherus shares to $44 from $43 and keeps a Buy rating on the stock, which is up $1.95, or 8.8%, to $24 in pre-market trading.
05/17/17
SBSH
05/17/17
NO CHANGE
Target $38
SBSH
Buy
Citi sees up to $8/share upside for Coherus on patent win
Citi analyst Mohit Bansal sees $4 to $8 per share upside for Coherus Biosciences (CHRS) after the Patent Trial and Appeal Board ruled in favor of the company's petitions for Inter Partes Review of AbbVie's (ABBV) '135 Patent. The stock in premarket trading is up 9%, or $1.95, to $24.00. The win makes a Humira biosimilar launch from Coherus more realistic, Bansal tells investors in a research note. Further, he believes the news makes an anti-TNF franchise partnership for Coherus with big bio-pharma more likely. He thinks a deal could be announced in the second half of 2017. Bansal keeps a Buy rating on Coherus with a $38 price target.
05/15/17
MAXM
05/15/17
NO CHANGE
Target $43
MAXM
Buy
Maxim sees probability of Humira patent ruling favoring Coherus
Maxim analyst Jason McCarthy said if Amgen's (AMGN) '135 patent for Humira is invalidated on May 17, Coherus Biosciences (CHRS) could potentially launch CHS-1420, its proposed biosimilar of adalimumab, in 2018, four years before others competing to launch a Humira biosimilar. He believes the probability favors Coherus, citing the fact that the company's focus on developing biosimilars is based on IP first. Coherus will need to raise capital again, but the outcome of the Humira patent decision and the upcoming approval decision for Neulasta on June 9 will determine at what valuation, said McCarthy, who has a Buy rating and $43 price target on Coherus shares.
05/05/17
05/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Cleveland Research. 2. Versartis (VSAR) initiated with an Overweight at Cantor. 3. Alder Biopharmaceuticals (ALDR) initiated with a Sell at UBS. 4. Playa Hotels & Resorts (PLYA) initiated with a Neutral at Citi. 5. Coherus Biosciences (CHRS) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

USLV

VelocityShares 3x Long Silver ETN

$12.17

0.39 (3.31%)

06:21
11/24/17
11/24
06:21
11/24/17
06:21
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$82.33

-0.23 (-0.28%)

06:20
11/24/17
11/24
06:20
11/24/17
06:20
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBB

iShares Nasdaq Biotechnology Index

$312.52

1.81 (0.58%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$5.34

-0.09 (-1.66%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$32.05

-0.15 (-0.47%)

, NKTR

Nektar

$49.75

-0.23 (-0.46%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Hot Stocks
Bayer announces INHALE Phase III clinical study did not meet primary endpoint »

Bayer (BAYRY) announced…

BAYRY

Bayer

$32.05

-0.15 (-0.47%)

NKTR

Nektar

$49.75

-0.23 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$26.02

0.02 (0.08%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$32.82

-0.22 (-0.67%)

06:18
11/24/17
11/24
06:18
11/24/17
06:18
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCMGY

Newcrest Mining

$18.13

0.2 (1.12%)

06:18
11/24/17
11/24
06:18
11/24/17
06:18
Downgrade
Newcrest Mining rating change  »

Newcrest Mining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$76.06

-0.16 (-0.21%)

06:16
11/24/17
11/24
06:16
11/24/17
06:16
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$47.81

0.12 (0.25%)

06:16
11/24/17
11/24
06:16
11/24/17
06:16
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$51.43

0.4 (0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$8.66

0.18 (2.12%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Upgrade
Centrica rating change  »

Centrica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$50.43

0.39 (0.78%)

, CBS

CBS

$56.24

-0.5 (-0.88%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Hot Stocks
Dish reaches multi-year carriage agreement with CBS, terms not disclosed »

DISH Network (DISH) has…

DISH

Dish

$50.43

0.39 (0.78%)

CBS

CBS

$56.24

-0.5 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$24.24

-0.19 (-0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$22.23

0.1881 (0.85%)

06:13
11/24/17
11/24
06:13
11/24/17
06:13
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$13.48

0.15 (1.13%)

06:10
11/24/17
11/24
06:10
11/24/17
06:10
Periodicals
Teva to slash up to 25% of Israeli workforce, Bloomberg reports »

Teva intends to cut as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

November PMI Composite…

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/24…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/13 Money…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

November PMI Composite…

02:45
11/24/17
11/24
02:45
11/24/17
02:45
General news
FX Update: The dollar has managed to find a footing »

FX Update: The dollar…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.